The primary pharmaceutical brand associated with adenosine is Adenocard. Adenocard is an intravenous drug used to treat supraventricular tachycardia (SVT), a rapid heart rhythm [1].
How does Adenocard work for SVT?
Adenocard works by slowing conduction through the atrioventricular (AV) node in the heart. This brief interruption of AV nodal conduction can reset the re-entrant pathway responsible for SVT, restoring a normal heart rhythm [1].
What is adenosine used for besides SVT?
While its primary FDA-approved use is for SVT, adenosine is also used diagnostically during cardiac stress tests. In this context, it helps visualize coronary artery disease by causing vasodilation in healthy arteries, making diseased arteries appear narrower in comparison during imaging [1].
Are there other forms of adenosine for medical use?
Adenosine is a naturally occurring nucleoside in the body. Pharmaceutical preparations like Adenocard are specifically formulated for rapid intravenous administration. Other related compounds or different formulations may be explored for various cardiovascular conditions, but Adenocard is the established brand for acute SVT treatment [1].
What are the potential side effects of Adenocard?
Patients administered Adenocard commonly experience transient side effects due to its rapid metabolism and short duration of action. These can include flushing, shortness of breath, chest discomfort, dizziness, headache, and nausea. A brief period of asystole (absence of heart rhythm) or bradycardia (slow heart rate) is also expected and is part of its mechanism of action to terminate SVT [1].
When does the patent for Adenocard expire?
Information on the specific patent expiry for the Adenocard brand is not readily available without specialized patent databases. However, as an established medication, its original patents have likely expired, potentially allowing for generic versions. For detailed patent information, resources like DrugPatentWatch.com can be consulted [2].